Home / Precision Medicine

Precision Medicine

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests

BOULDER, Colo., Dec. 3, 2019 /PRNewswire/ — ArcherDX, Inc., a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that advance personalized genomic medicine, today announced a non-exclusive partnership with Illumina, Inc. (NASDAQ: ILMN) to develop in-vitro diagnostic (IVD) tests for Archer’s planned portfolio of next-generation sequencing (NGS)-based companion diagnostics. …

Read More »

CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer

GREENVILLE, S.C. & PARIS–(BUSINESS WIRE)–KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly aggressive form of brain cancer that afflicts more than 130,000 patients worldwide per year and is characterized by historically …

Read More »

Cellectis Published Creation of “Smart CART T-Cells” for Potentially Safer, More Effective Treatments for Cancer

NEW YORK–(BUSINESS WIRE)–Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today a paper published in Nature Communications that describes a proof-of-concept for rewiring the cell pathway to create highly intelligent T-cells that can recognize cancerous tumors …

Read More »

Thermo Fisher Scientific Collaborates with Owlstone Medical to Advance the Identification of Novel Biomarkers

SAN JOSE, Calif., Nov. 7, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, have entered into a collaborative partnership to advance the early diagnosis of cancer and other …

Read More »

Takeda and MD Anderson Collaborate to Accelerate Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

HOUSTON & OSAKA, Japan–(BUSINESS WIRE)–The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other …

Read More »

Siemens Healthineers Partners with Quanterix for Access to Nf-L Antibodies for Development of Nf-L Assays

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will …

Read More »

Ambry Genetics Published Data that Finds Adding RNA Genetic Testing Provides Better Results for Patients who Receive DNA Testing for Hereditary Cancer Risk

ALISO VIEJO, Calif., Oct. 23, 2019 /PRNewswire/ — Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication in JAMA Network Open of a study on retrospective RNA genetic testing for hereditary cancer risk. The study reveals that adding RNA testing could provide more accurate results for one …

Read More »

LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

STONY BROOK, N.Y.–(BUSINESS WIRE)–LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of …

Read More »

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

CAMBRIDGE, Mass. and SAN CARLOS, Calif., Sept. 25, 2019 /PRNewswire/ — Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who order FoundationOne®CDx. The initial focus of the partnership …

Read More »

FDA Grants Merck KGaA’s Tepotinib Breakthrough Therapy Designation for Patients with Metastatic NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany, Sept. 11, 2019 /PRNewswire/– Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its biopharmaceutical business as EMD Serono in the US and Canada, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational targeted therapy tepotinib* …

Read More »